OS Therapies Incorporated logo

OS Therapies Incorporated (OSTX)

Market Closed
14 Feb, 20:00
AMEX AMEX
$
2. 19
+0.2
+10.05%
After Hours
$
2. 07
-0.12 -5.48%
- Market Cap
- P/E Ratio
0% Div Yield
38,600,400 Volume
- Eps
$ 1.99
Previous Close
Day Range
2.16 2.98
Year Range
1.58 7

Summary

OSTX closed today higher at $2.19, an increase of 10.05% from yesterday's close, completing a monthly decrease of -49.54% or $2.15. Over the past 12 months, OSTX stock lost -49.54%.
OSTX is not paying dividends to its shareholders.
The last earnings report, released on Nov 15, 2024, missed the consensus estimates by -0.18%. On average, the company has fell short of earnings expectations by -0.18%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on AMEX (USD).
Want to track OSTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

OSTX Chart

OS Therapies Incorporated (OSTX) FAQ

What is the stock price today?

The current price is $2.19.

On which exchange is it traded?

OS Therapies Incorporated is listed on AMEX.

What is its stock symbol?

The ticker symbol is OSTX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has OS Therapies Incorporated ever had a stock split?

No, there has never been a stock split.

OS Therapies Incorporated Profile

Biotechnology Industry
Healthcare Sector
Mr. Paul A. Romness M.P.H. CEO
AMEX Exchange
- ISIN
United States Country
3 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

OS Therapies Incorporated stands as a clinical stage biopharmaceutical company committed to the advancement of treatments for osteosarcoma and other solid tumors. The company is actively engaged in the identification, development, and commercialization phases of novel treatments. With its foundation laid in 2018 and headquartered in Rockville, Maryland, OS Therapies Incorporated has made significant strides towards offering innovative solutions in the fight against cancer.

Products and Services

  • OST-HER2:

    An off-the-shelf immunotherapy candidate developed by OS Therapies Incorporated, OST-HER2 represents a pivotal development in the landscape of cancer treatment. Designed to harness the body's immune system to fight cancer, this product exemplifies the company's commitment to innovative cancer treatment paradigms.

  • OST-TDC:

    A next-generation tunable antibody-drug conjugate (ADC), OST-TDC features a state-of-the-art plug-and-play platform with tunable pH-sensitive silicone linkers. This technology allows for the precise targeting and delivery of cancer therapeutics, showcasing OS Therapies Incorporated's forefront position in advancing ADC technologies for cancer treatment.

Contact Information

Address: 15825 Shady Grove Road
Phone: 410-297-7793